EXTRACELL BIOTECHNOLOGIES: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
EXTRACELL BIOTECHNOLOGIES
Largest movements
- Cash +€140
up €140 (+933%), from €15 to €155
mainly Trade debts (+€6,140)
- Receivables within one year +€44
up €44 (+15.4%), from €286 to €330
- Trade debts +€6,140
up €6,140 (+2,717%), from €226 to €6,366
- Other debts -€4,058
down €4,058 (-61.7%), from €6,574 to €2,516
- Profit (loss) carried forward -€1,898
down €1,898 (-11.5%), from -€16,499 to -€18,397
- Gross operating margin +€12,167
up €12,167 (+86.8%), from -€14,019 to -€1,852
- Turnover +€7,500
new in 2025: €7,500
- Purchases and services -€4,666
down €4,666 (-33.3%), from €14,019 to €9,353
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €301 | €485 | +€184 | +61.1% |
| Current assets | 29/58 | €301 | €485 | +€184 | +61.1% |
| Amounts receivable within one year | 40/41 | €286 | €330 | +€44 | +15.4% |
| Other amounts receivable | 41 | €286 | €330 | +€44 | +15.4% |
| Cash at bank and in hand | 54/58 | €15 | €155 | +€140 | +933% |
| Total equity and liabilities | 10/49 | €301 | €485 | +€184 | +61.1% |
| Equity | 10/15 | -€6,499 | -€8,397 | -€1,898 | -29.2% |
| Contributions | 10/11 | €10,000 | €10,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€16,499 | -€18,397 | -€1,898 | -11.5% |
| Amounts payable | 17/49 | €6,800 | €8,882 | +€2,082 | +30.6% |
| Amounts payable within one year | 42/48 | €6,800 | €8,882 | +€2,082 | +30.6% |
| Trade debts | 44 | €226 | €6,366 | +€6,140 | +2,717% |
| Suppliers | 440/4 | €226 | €6,366 | +€6,140 | +2,717% |
| Other amounts payable | 47/48 | €6,574 | €2,516 | -€4,058 | -61.7% |
| Turnover | 70 | - | €7,500 | +€7,500 | |
| Goods, raw materials, services and sundry goods | 60/61 | €14,019 | €9,353 | -€4,666 | -33.3% |
| Gross operating margin | 9900 | -€14,019 | -€1,852 | +€12,167 | +86.8% |
| Operating profit (loss) | 9901 | -€14,019 | -€1,852 | +€12,167 | +86.8% |
| Financial charges | 65/66B | €25 | €46 | +€21 | +84.0% |
| Recurring financial charges | 65 | €25 | €46 | +€21 | +84.0% |
| Profit (loss) for the period before taxes | 9903 | -€14,044 | -€1,898 | +€12,146 | +86.5% |
| Profit (loss) for the period | 9904 | -€14,044 | -€1,898 | +€12,146 | +86.5% |
| Profit (loss) for the period to be appropriated | 9905 | -€14,044 | -€1,898 | +€12,146 | +86.5% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 28 October 2026 via checked.be.